Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer.
Publication/Presentation Date
3-1-2026
Abstract
PURPOSE: Anaplastic thyroid cancer (ATC) is a rare and highly aggressive malignancy with limited treatment options. Currently, the only US Food and Drug Administration-approved targeted therapies for ATC are directed at
METHODS: We queried the American Association for Cancer Research Project GENIE database (v18.0) via cBioPortal for somatic PGVs in ATC tumors. This multi-institutional data set provides next-generation sequencing and clinical data across cancer types. Genes were grouped by pathway relevance: MAPK (
RESULTS: A total of 350 ATC tumor samples were analyzed. PGVs were identified in MAPK pathway genes in 57.7% of tumors, PI3K/Akt/mTOR pathway genes in 26.6%, HRD-associated genes in 8.0%, and MMR-associated genes in 3.7%. In total, 72.0% (252/350) of tumors harbored at least one PGV in one or more of these potentially targetable pathways.
CONCLUSION: Somatic PGVs in potentially targetable pathways were found in 72% of ATC tumors. Given the aggressiveness of ATC and the limited efficacy of current treatments, these findings support the rationale for biomarker-driven basket trials investigating the efficacy of targeted therapies in this population.
Volume
10
Issue
3
First Page
2500655
Last Page
2500655
ISSN
2473-4284
Published In/Presented At
Qazi, M., Ahsan, M. D., Telvizian, T., Laiacona, S., Ahmad, N., & McHugh, T. (2026). Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer. JCO precision oncology, 10(3), e2500655. https://doi.org/10.1200/PO-25-00655
Disciplines
Medicine and Health Sciences
PubMedID
41849729
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article